Hundreds of Millions at Risk: Vaccine Against Dangerous Tropical Parasite Shows Promising Early Results

A new experimental vaccine against schistosomiasis has demonstrated two key properties required for effective immune protection: it not only triggers a strong immune response but also establishes long-term immune memory, enabling the body to respond more rapidly to future infections. These findings are reported in a new study published in the journal npj Vaccines.

The research focuses on the development of a vaccine called SchistoShield, led by Afzal Siddiqui at Texas Tech University Health Sciences Center. Siddiqui has spent several decades working on the project with the goal of creating a vaccine capable of both preventing infection and reducing the severity of established disease.

Schistosomiasis is a parasitic disease caused by flatworms that live in freshwater. Their larvae penetrate human skin upon contact with contaminated water and mature into adult parasites inside the body.

The parasites produce eggs that trigger inflammation and widespread organ damage. The disease is endemic in nearly 80 countries, primarily across sub-Saharan Africa. According to the World Health Organization, around 250 million people are currently infected, while another 800 million remain at risk.

Despite its widespread impact, schistosomiasis is classified as a neglected tropical disease because it primarily affects impoverished communities. At present, only one drug is available to treat the infection, but it does not prevent reinfection, highlighting the urgent need for an effective preventive vaccine.

According to the new study, blood samples collected from participants in clinical trials conducted in the United States and several African countries showed a durable immune response following SchistoShield vaccination. Researchers observed activation of both B cells and T cells, indicating the development of long-lasting immune memory.

The authors report that in both preclinical studies and early-stage clinical trials, the vaccine induced a robust cellular immune response and established immunological memory—considered a critical hallmark of a potentially effective vaccine against parasitic infections.

Siddiqui noted that the current findings are based on relatively small study groups of between 50 and 100 participants. He emphasized that these are still early-stage results and that large-scale clinical trials involving thousands of volunteers will be required to confirm the vaccine's efficacy.

The developers stress that the project has been humanitarian in nature from the outset, focusing on combating a disease that disproportionately affects low-income populations. Support from university programs, federal grants, and international charitable organizations has enabled the research to continue without a commercial profit motive.

According to university officials, the project's ultimate goal is to improve access to healthcare and provide a tool capable of significantly reducing the global burden of one of the world's most widespread parasitic diseases.